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One of the fundamental attributes of proton therapy and carbon ion therapy is the ability 
of these charged particles to spare tissue distal to the targeted tumor. This significantly 
reduces normal tissue toxicity and has the potential to translate to a wider therapeutic 
index. Although, in general, particle therapy also reduces dose to the proximal tissues, 
particularly in the vicinity of the target, dose to the skin and to other very superficial tis-
sues tends to be higher than that of megavoltage x-rays. The methods presented here, 
namely, “interleaved carbon minibeams” and “radiosurgery with arrays of proton and
light ion minibeams,” both utilize beams segmented into arrays of parallel “minibeams” 
of about 0.3 mm incident-beam size. These minibeam arrays spare tissues, as demon-
strated by synchrotron x-ray experiments. An additional feature of particle minibeams is 
their gradual broadening due to multiple Coulomb scattering as they penetrate tissues. 
In the case of interleaved carbon minibeams, which do not broaden much, two arrays 
of planar carbon minibeams that remain parallel at target depth, are aimed at the target 
from 90° angles and made to “interleave” at the target to produce a solid radiation field 
within the target. As a result, the surrounding tissues are exposed only to individual
carbon minibeam arrays and are therefore spared. The method was used in four-direc-
tional geometry at the NASA Space Radiation Laboratory to ablate a 6.5-mm target in a 
rabbit brain at a single exposure with 40 Gy physical absorbed dose. Contrast-enhanced 
magnetic resonance imaging and histology 6-month later showed very focal target
necrosis with nearly no damage to the surrounding brain. As for minibeams of protons 
and light ions, for which the minibeam broadening is substantial, measurements at MD 
Anderson Cancer Center in Houston, TX, USA; and Monte Carlo simulations showed
that the broadening minibeams will merge with their neighbors at a certain tissue depth 
to produce a solid beam to treat the target. The resulting sparing of proximal normal tis-
sue allows radiosurgical ablative treatments with smaller impact on the skin and shallow 
tissues. This report describes these two methods and discusses their potential clinical 
applications.
 
 
 
 
Keywords: proton therapy, light-ion therapy, carbon therapy, proton minibeams, light-ion minibeams, carbon 
minibeams, tissue-sparing effect, interleaved carbon minibeams
FigUre 1 | Depth-dose distributions from 10 MV x-rays, proton 
beams, and carbon ion beams superimposed with each other for 
comparison.
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inTrODUcTiOn
The first utilization of segmented beams to increase superficial 
normal tissue tolerance to radiation was in grid therapy (1). The 
method was used in conjunction with 250-kVp orthovoltage 
x-rays in the early twentieth century to ameliorate the skin dam-
age produced during radiation therapy of deeply seated tumors 
because of the low-dose penetration of the low-energy x-rays. 
The method involved positioning metal grids with openings as 
large as 2  cm on the patient’s skin. The resulting skin-sparing 
effect was solely due to the “dose–volume effect” according to 
which the tissue’s tolerance to radiation increases as its volume 
decreases (2, 3). Dose–volume is also the basis for all techniques 
of stereotactic radiosurgery [see, for example, Ref. (4)] in which 
high doses can be given to small targets, sometimes in a single-
dose fraction.
Although the introduction of the megavoltage (MV) x-ray 
machines into radiation therapy, which occurred in the mid-
dle of the twentieth century, solved the problem of damage 
to the skin and other proximal tissues from low-energy 
orthovoltage x-rays the challenge to find better beams for 
radiation therapy did not go away. This is because the dose 
distribution produced in tissues from MV x-rays is far from 
ideal. As seen in Figure 1, they give unnecessary dose to the 
normal tissues surrounding the target both proximal and 
distal to the target. Furthermore, their lateral dose penumbra 
is very large. Although proton and carbon ion beams clearly 
produce a better dose confinement at the target because of 
their Bragg-Peak feature, they both lack the shallow-tissue-
sparing effect of high-energy x-rays, which is considered a 
significant shortcoming.
Two major developments that occurred since the time of 
grid therapy in experimental radiation therapy indicate a great 
potential for segmented beams at much smaller beam sizes than 
those used in grid therapy to improve radiation therapy. First, 
Zeman et al. (5–7), studying the tolerance of the mouse cerebel-
lum to pencil beams of 25-μm to 1-mm diameter in the 1950s, 
showed that the mouse cerebellum tolerates the smaller beams 
considerably better than 1-mm beams. Specifically, microscopic 
beams of 25 and 75 μm did not cause tissue necrosis (i.e., loss of 
the tissue’s blood perfusion) at doses up to 10,000 Gy, although 
they lead to neuronal cell death in their direct beam path, while 
1-mm beams of 120–300 Gy literally ablate brain tissues at certain 
time points within the 24–120 days post-irradiation; these results 
include 300 Gy (5) and 140 Gy (7) ablations at 24 days and 280 Gy 
ablation at 120 days (6). Second, it was shown in the 1990s that 
the rat cerebellum tolerates arrays of parallel, very thin planes 
of synchrotron x-rays at very high doses. Specifically, Slatkin 
et al. showed at the National Synchrotron Light Source (NSLS), 
Brookhaven National Laboratory (BNL) that arrays of parallel, 
37-μm synchrotron x-rays, spaced 75 μm on-center (microbeams) 
of ~50 keV median energy were tolerated by the rat cerebellum 
at up to 250 Gy in-beam in-depth without producing any visible 
effect on the H&E-stained brain tissue 3 months later (8). The 
excitement produced by the observed tissue-sparing effect led 
to the start of a new line of research at both the NSLS and the 
European Synchrotron Radiation Facility (ESRF) in Grenoble, 
France, called microbeam radiation therapy (MRT) (9–16). The 
early experiments in both these labs included measuring the 
tolerance of the central nervous system (CNS) in very young 
animals to very high doses of x-ray microbeams; these included 
brains of duck embryos irradiated to 120 Gy (9) and cerebella of 
suckling rats and weanling piglets irradiated to 300 Gy (13). We 
note that it has become a convention in the field of MRT to call 
beams with 0.3-mm size and larger “minibeams.”
The effects observed in the above studies were categorically 
different from grid therapy in two ways. First, it showed that tis-
sues much deeper that skin can tolerate huge doses, and second, 
as shown in the presentation of mechanistic bases for this larger 
tissue tolerance later in this report, the effect goes far beyond the 
dose–volume effect and involves what is called “prompt micro-
scopic biological repair effect” including capillary blood vessel 
repair (10–12, 14, 16).
The next major development in the field occurred some 
10 years later when it was shown at the NSLS that arrays of syn-
chrotron X-ray microbeams as thick as 0.68 mm (minibeams) still 
retain much of their tissue-sparing effect in the rat spinal cord and 
brain (17). Furthermore, it showed that two such arrays aimed at 
the target from 90° angles, with gaps between the beams equal to 
the minibeams’ thickness, can be “interleaved” (or “interlaced”) 
to produce a solid radiation field at the target (17) (Figure 2A). 
The method was used with 0.68  mm beams to ablate a 3-mm 
target in a rat brain at 120 Gy with a solid interlaced beam at the 
target; very little damage was observed in the H&E-stained tissue 
outside the target (17).
The above finding about the sizable tissue-sparing effect of 
minibeams as thick as 0.7-mm opened the way for charged parti-
cle minibeams to be evaluated in similar preclinical studies. The 
first such evaluation was with carbon ion minibeams at the NASA 
Space Radiation Laboratory (NSRL) at BNL. They were used in 
FigUre 2 | schematic views of interleaved x-ray minibeams and two- and four-directional interleaved carbon minibeams.
FigUre 3 | Treating a target in the brain with proton minibeams: 
(a) schematic view of exposures from three orthogonal directions, 
(B) Monte carlo simulation of a single exposure on the background  
of a brain Mri.
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the “interlaced” (or “interleaved”) geometry (Figures  2B,C) to 
ablate a small target in the rabbit brain (18). The rabbits evalu-
ated in 6  months with contrast-enhanced magnetic resonance 
imaging (MRI) and histology showed virtually no damage 
to the surrounding tissues. The method, however, could not 
be implemented with protons and light ions because of their 
excessive broadening with tissue depth. However, it was shown 
through dosimetric measurements with proton minibeams and 
Monte Carlo simulations with proton and light-ion minibeams 
that minibeams in such arrays can be designed to merge with 
their neighbors at a certain depth in the subject to produce a solid 
beam for treating targets while sparing the skin and other shallow 
tissues (19) (Figure 3).
MaTerials anD MeThODs
Although the minibeams’ decline of tissue sparing with increas-
ing beam size is gradual; nevertheless, any treatment planning 
with minibeams will require defining an upper size limit for the 
minibeams’ usage. For the following reasons, we suggest that this 
limit will be set at 0.7 mm. First, studies with 0.68 mm planar 
synchrotron x-ray minibeams with 0.68 mm gaps between them 
showed that irradiation of nearly the entire rat brain with these 
beam arrays at 170  Gy beams were greatly tolerated for the 
7-month period of observation (17). Specifically, not only did the 
rats not demonstrate any neurological or histological deficits but 
they also gained weight normally (17). On the other hand, studies 
by Zeman et  al. with 1 mm diameter 25-MeV deuteron pencil 
beams demonstrated complete tissue ablation of the mouse cer-
ebellum at doses as little as 140 Gy within 280 days. These results 
indicate that the minibeams’ tissue-sparing effect declines quite 
sharply at beam dimensions beyond 0.68 mm. Although 0.7-mm 
might be considered a conservative upper limit, its choice is justi-
fied because possible clinical use of charged particle minibeams 
will require very high incident doses to produce adequate target 
doses.
The incident minibeam width of 0.3-mm used in all experi-
mental and simulation studies presented below was chosen in 
the context of the above consideration for the upper limit of 
the allowable minibeam size. It provides us with some dynamic 
maneuvering range of the beam thickness before reaching the 
upper limit. We also point out that choosing incident beams 
smaller than 0.3 mm is technically difficult, and at the same time 
it does not add much to that maneuvering range. As for the choice 
of the array’s minibeam spacing, an on-center value of 0.7-mm 
seems to ideal for most cases because it makes the minibeams 
merge with each other immediately after they reach their maxi-
mum allowable size.
interleaved carbon Minibeams
The rabbit study described below was carried out in accordance 
with the recommendations of the Institutional Animal Care 
and Use Committee (IACUC) of BNL. BNL is accredited by the 
American Association for Accreditation of Laboratory Animal 
Care, Inc. (AAALAC). The protocol was approved by the BNL’s 
IACUC.
Figure  4 shows the schematic view of the four-directional 
interleaved carbon ion minibeams used to ablate a 6.5-mm 
target in a rabbit brain (18). The details were the following. The 
minibeams’ incident-beam thickness was 0.3 mm, and their beam 
spacing on-center was 1.05 mm on-center; this spacing was much 
larger than twice the incident-beam thickness to accommodate 
the gradual minibeam broadening in tissues. Figure  5 shows 
a “to-scale” presentation of two of the four carbon minibeam 
arrays used in the study. The study used 124–135 MeV/nucleon 
carbon energies to create the spread-out-Bragg-peak (SOBP). 
The total dose produced at the target from all four directions in 
the SOBP was 40 Gy physical absorbed dose, which corresponds 
FigUre 5 | Two-directional interleaved carbon minibeams drawn to 
scale for the rabbit experiment.
FigUre 4 | schematic view of the rabbit head irradiated with 
four-directional interleaved carbon minibeams.
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to 120 photon-equivalent Gy (GyE) using an average relative 
biological effectiveness value of 3.0 at the target. The following 
dosimetry account shows that this dose was produced by mini-
beams of 14 Gy in-beam incident physical dose in each of the four 
interleaving arrays. First, it was shown (18) that the particular 
geometry involving 14 Gy “pedestal” incident dose leads to 20 Gy 
physical dose at the SOBP. Therefore, the target dose would have 
been 20 Gy (and not 40 Gy) if we had only two interleaving arrays 
(see Figure 2B for geometry). The 40-Gy physical target dose was 
produced by virtue of having a four-directional incident-beam 
geometry (Figure 2C).
Proton and light-ion Minibeams
Figure  3A is a schematic representation of treating a brain 
tumor with three minibeams arrays aimed at the target from 
mutually orthogonal angles, whereas Figure  3B presents the 
results of Monte Carlo simulations of minibeams’ merging 
in one such array and overlaid on a clinical MRI scan of the 
brain. The method’s physical feasibility was established by 
measurements at MD Anderson Cancer Center and by Monte 
Carlo simulations (19).
The measurements at the MD Anderson Proton Therapy 
Center included the broadening rate on chromographic film of 
a 109-MeV proton pencil beams with 0.3-mm incident-beam 
diameter. The beams were produced by a pinhole collimator made 
of a 1-cm thick tungsten–copper alloy and the measurements 
were carried out using a stack of radiochromic films interspersed 
with 2-mm plastic sheets positioned downstream of the collima-
tor. The film stack was irradiated to 10 Gy peak dose to measure 
the minibeam’s broadening (19). In another measurement, a 
pattern of 100 MeV planar proton minibeams of 0.3-mm thick-
ness, spaced 1-mm on-center was captured on a chromographic 
film (19); the minibeam array was produced using a 5-cm thick 
tungsten multislit collimator.
resUlTs
interleaved carbon Minibeams
The carbon minibeams’ rate of beam broadening with tissue 
depth is quite suitable for interleaved carbon minibeams of target 
sizes such as that of the brain but not for larger sizes. In this 
regard, the criterion is that the minibeams’ width at the proxi-
mal side of the target should not substantially exceed 0.7  mm 
where their tissue-sparing effect starts to gradually diminish. 
For example, in the above study, a minibeam width of 0.525 mm 
was produced at the target’s proximal side, which was 36-mm 
deep (tissue equivalent) (18). This broadening is in agreement 
with the criterion that in the method’s future clinical application 
the maximum allowable depth of the proximal side of the target 
is 6.5 cm; heavier ion beams such as oxygen might be used for 
treating deeper tumors (18).
The rabbit, observed for 6 months, did not show any behavioral 
deficits. Contrast-enhanced MRI showed extensive gadolinium 
contrast leakage only from the target tissue but not the surround-
ing tissues. Furthermore, H&E tissue staining showed a necrotic 
target tissue with no sign of damage and a slide only 5.5 mm away 
from the center of the target showed no damage along the four 
interleaving beam arrays (18).
Proton and light-ion Minibeams
Figure  6 shows the measured minibeam broadening rate for 
109-MeV proton pencil beams superimposed with the Monte 
Carlo simulations of the same minibeam width in water. The 
experimental minibeam width was defined as the full width at 
half-maximum of the beam’s image on the digitized film. The 
figure shows that the measured and the simulated 0.7-mm beam 
width for this beam energy are reached at 22 and 23.5  mm, 
respectively (19).
Figure  7 shows a schematic view of a three-dimensional 
minibeam converging in an array of proton pencil minibeams 
with 0.3-mm incident-beam thickness and 0.7-mm beam spac-
ing on-center. It demonstrates the physical feature of the event, 
emphasizing the effect of the acceleration of the broadening rate 
as the beam approaches the merging point. This acceleration can 
FigUre 8 | Monte carlo simulation of the broadening rates in water of 
0.3-mm pencil-shaped (solid marks) and planar (hollow marks) 
minibeams of protons, deuterons, and he-4 and li-7 ions, all at the 
incident-beam energy, leading to 10-cm depth in water.
FigUre 7 | Monte carlo simulations of a three-dimensional pattern of 
proton pencil minibeams converging at a target.
FigUre 6 | Proton pencil minibeams’ broadening for 109 MeV beam 
energy (circles: film measurements; x marks: the simulations in 
water).
FigUre 9 | Monte carlo simulation of the dose distribution with depth 
in water of the 0.3-mm proton and li-7 planar minibeam arrays of 
Figure 8, spaced 1.0-mm on-center.
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be clearly seen also in Figure 8 that shows the Monte Carlo simu-
lation results of the broadening rates of 0.3-mm pencil-shaped 
and planar minibeams of protons, deuterons, and helium 4 and 
lithium 7 ions penetrating water at incident energies leading to 
10 cm water depth. The acceleration effect of the beam broaden-
ing is clearly manifested by the curving-up feature of the curves.
Finally, Figure  9 shows the two-dimensional pattern of the 
minibeam broadening for the planar minibeams of protons and 
lithium 7 of Figure 8, with 1.0 mm minibeam spacing on-center. 
The simulations indicate that water depths at which the mini-
beams in these two arrays fully merge with their neighbors are 29 
and 56 mm, respectively (19).
DiscUssiOn
The data and perspectives presented in this section are mostly 
discussions related to the clinical potential of interleaved carbon 
minibeams and gradually broadening arrays of proton and 
light-ion minibeams that converge at the tumor. In the course of 
this discussion, comparison is made with the radiation therapy 
methods currently in clinical use, including MV x-rays, protons, 
December 2015 | Volume 5 | Article 2696
Dilmanian et al. Charged Particle Therapy with Mini-Segmented Beams
Frontiers in Oncology | www.frontiersin.org
and carbon ions. In this context, an important subject is the 
incident dose in the individual minibeams, which are clearly 
much higher than those used in the incident conventional beams 
to make up for the non-irradiated tissue slices residing between 
the incident minibeams.
Comparing interleaved carbon minibeams with conventional 
carbon therapy the advantage is smaller radiation impact on the 
non-targeted tissues, particularly the proximal tissues. This can 
allow reducing the number of dose fractions and/or increasing 
the target dose, which can be important in treating radioresistant 
tumors.
Comparing proton minibeams with conventional proton 
therapy, the advantage is mostly saving the skin and the 
proximal tissues. The method’s application can include the 
facilitation of dose hypofractionation. But, most importantly, 
the method can reduce the damage to certain eloquent and/or 
radiosensitive organs in the brain such as the cerebral cortex 
that is involved in gliogenesis, especially in children (20), and 
therefore its sparing may reduce cognitive deficits. The method 
can also reduce the integral biological brain dose, another 
important factor in reducing cognitive deficits when targets in 
the brain are treated (21–23).
Comparing both methods with conventional MV x-ray 
methods such as intensity-modulated radiation therapy (IMRT), 
radiosurgery, and stereotactic body radiotherapy (SBRT), the 
advantages include all advantages of the corresponding conven-
tional charged-particle methods together with the above advan-
tage of the minibeam-implemented charged-particle methods. 
For both methods that include the Bragg-peak feature of the 
particle methods, while for carbon therapy, it also includes larger 
target RBE and smaller lateral dose falloff.
Mechanisms Underlying the  
Tissue-sparing effect of the X-ray 
Microbeams and Minibeams
The microbeams’ tissue-sparing effect is thought to be based on 
two phenomena, namely, the “dose–volume effect” (2, 3) and the 
“prompt, microscopic, biological repair effect” (10–12, 14, 16). 
As indicated above, dose–volume effect means that the tissue’s 
tolerance to radiation increases as the volume of the irradiated 
tissue decreases (2, 3). The effect, valid for any target size, has 
been the basis for grid therapy (1) and stereotactic radiosurgery 
(4). On the other hand, the prompt, microscopic, biological repair 
is specific to microbeams and minibeams at beam sizes below 
about 0.7  mm. It is primarily related to the fast (within hours 
and days) repair of the capillary blood vessels via the regenera-
tion of angiogenic cells surviving between the microbeams and 
minibeams (10, 12).
Quantitative estimation of the Magnitude 
of the Minibeams’ Tissue-sparing effect
One can quantitatively compare the maximum tolerance of the 
rat brain to minibeams and solid beams using Ref. (17, 24), 
respectively. While in the former, the entire brain tolerated, 
both behaviorally and histologically, 0.68 mm planar minibeams 
with 0.68-mm gaps between them at 170  Gy for the 7-month 
observation period (17), the latter’s local 22.5-Gy solid beam 
irradiation led to “histological evidence for the development of 
necrosis in the white matter after a latent period of >26 weeks” 
(24). This puts the dose-tolerance advantage of minibeams to that 
of solid beams over 7.5-fold.
Magnitude of the incident-Beam Doses in 
clinical interleaved carbon Minibeams
Comparing the incident dose in 0.3-mm carbon minibeams 
spaced 0.7-mm on-center to carbon solid beams, both deliver-
ing the same target dose from two 90° incident directions, the 
minibeams’ incident dose should be 4- to 4.7-times larger. This 
is because (a) doses from 90°-pairs of interleaving arrays do 
not add up and (b) minibeams’ dose is diluted by 2- to 2.33-
fold (0.7/0.3 ratio for 0.3 minibeams broadening to 0.7  mm 
just before the target) on the way to the target because of their 
beam broadening. This high dose of 0.3-mm carbon minibeams 
should be well tolerated by the skin and the other proximal 
tissues because as discussed above the tolerance advantage of 
0.68-mm minibeams with 0.68-mm gaps between them over 
solid beams in about 7.5:1.0, and therefore that of 0.3 minibeam 
with 0.4-mm gaps between them should be even higher, prob-
ably over 10-fold. Therefore, a 4.7-fold higher dose in the inci-
dent minibeams compared to a solid beam should be tolerable.
Magnitude of the incident-Beam Doses of 
Protons and light-ion Minibeams
Comparing the incident dose in 0.3-mm proton or light-ion 
minibeams spaced 0.7-mm on-center to that of proton or 
light-ion solid beams, both delivering the same target dose, the 
incident minibeam dose should be 2.3-fold higher when using 
planar minibeams and 6.9-fold higher when using pencil-shaped 
minibeams. This is because of the much smaller yield of the 
collimator producing pencil-shaped beams. Although using 
the above argument for the much higher tissue tolerance of the 
tissues to minibeams than solid beams the proton minibeams 
should still be tolerated, the clinical utilization of the pencil-
shaped beams seems less attractive. This problem, however, 
is solved with the use of light-ion minibeams such as He-4 or 
Li-7 because the smaller rate of minibeams broadening allows 
the use of smaller than 0.7-mm beam spacing on-center to still 
spare several centimeters of proximal tissues. In that regards, the 
collimator yield for 0.3-mm beams spaced 0.5-mm on-center is 
28.3% compared to 14.4% for 0.7-mm pencil-beam spacing, and 
the minibeams dose will be only be 3.5-fold higher than that from 
incident solid beams.
comparing the Dose–Depth Distributions 
in a Brain Tumor Phantom Produced by 
MV X-rays, solid Proton Beams, and 
Proton Minibeams
Although the “biological dose” from incident proton minibeams 
cannot be calculated without detailed experiments, a rough 
estimate of the dose can be made through our knowledge of the 
magnitude of minibeam’s tissue-sparing effect. Here, we compare 
the dose–depth distributions in a 15-cm deep water phantom of 
FigUre 10 | comparing the depth-dose distributions in a phantom of 
(a) a 10-MV x-ray beam, (b) an incident solid proton beam with its 
spread-out Bragg-peak, and (c) estimated biological dose from an 
incident proton minibeam array undergoing the same pattern of 
Bragg-peak spreading as above.
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(a) a 10-MV x-ray beam, (b) an incident solid proton beam with 
its SOBP over a 2.5-cm target starting at 5.5-cm depth from the 
surface, and (c) estimated biological dose from an incident array 
of proton minibeams merging into a solid beam at 2.5-cm depth, 
which has undergone the same pattern of Bragg-peak spreading 
as the solid proton beam (Figure 10). As seen in this figure, the 
entrance biological dose of the proton minibeams is set to 1/3 of 
the physical dose of the solid proton beams. This estimate is the 
product of two factors. First, the incident dose in each minibeams 
should be 2.3 times (for 0.3-mm minibeams spaced 0.7-mm on-
center) that of the solid beam to make up for the un-irradiated 
slices of tissue between the minibeams. Second, the magnitude 
of the tissue-sparing effect for 0.3-mm minibeams is estimated 
to be sevenfold from the earlier discussion in this section. This 
makes the biological dose compared to the solid beam of protons 
2.3/7.0 = 0.33. In other words, despite the 2.3-fold larger in-beam 
physical dose needed, still the biological dose is only 33% of 
the physical dose of the incident solid proton beam. The figure 
pictorially demonstrates the tissue-sparing effect of the proton 
minibeams in shallow tissues and their contribution to reduce 
the integral brain dose.
Potential clinical challenges
The use of interleaved carbon minibeams requires the immobi-
lization of both the proximal tissues and the target tissues. This 
limits the method’s clinical applications to benign and malignant 
tumors of the brain and spinal cord, neurological targets, head-
and-neck tumors, breast cancer (with the breast immobilized), 
and tumors of the spinal column and the extremities. The 
neurological targets may include those that give rise to epilepsy, 
trigeminal neuralgia, tremor, and obsessive compulsive disorder. 
As a remote possibility, the method might be applicable to treat 
tumors of the chest and abdomen such as those of the liver and 
pancreas when administered under anesthesia as a single fraction.
However, the requirements for proton and light-ion 
minibeams are much more relaxed. There, the immobilization 
requirements apply only to the proximal tissues that have to be 
spared, and not to any deeper normal tissues or the target. Since 
the tissue-sparing range of proton minibeams is only 2–3 cm tis-
sue depth, abdominal target can be treated by immobilizing the 
shallow tissues by physical means using the multislit collimator 
or a frame positioned in front of it. Of course, all possible applica-
tions indicated above for carbon minibeams can also be treated 
with proton and light-ion minibeams.
A legitimate concern regarding proton and light-ion mini-
beams pertains to the dose to the patient from the neutrons pro-
duced in the multislit collimator. Best estimates of this dose are 
that they are a very small fraction of the incident dose, even when 
accounting for biological effectiveness of neutrons. In addition, 
they can be further reduced by introducing an air gap between the 
collimator and the subject’s skin. This issue was further discussed 
more recently with the journal following a Letter to the Editor 
(25). The conclusion was that for protons and for a 5-cm gap 
between the collimator and the skin the dose will be about 1% 
of the peak target dose. Because the gap can be made larger that 
5-cm we do not expect this issue to be a major factor in charged 
particle minibeam therapy.
ease of clinical implementation
Both methods can be readily integrated into current clinical 
practice of carbon therapy, proton therapy, or light-ion therapy by 
positioning a multislit collimator in the path of the broad incident 
beam. They are entirely compatible with passively scattered beam 
or spot-scanned beams. Interleaved carbon minibeams require 
two of four 90° irradiations, while the treatment with protons 
and light-ion minibeams could also ideally be done at 90° angles 
to avoid production of tissue irradiations with shallow-angle 
minibeam exposures producing incomplete tissue-sparing in 
these areas, called minibeam star artifacts. Also, two fixed hori-
zontal beam-lines aiming at the target from 90° could be used for 
simultaneous administration of two arrays. Finally, both methods 
can be administered in the raster scanning mode, thus further 
reducing the dose to the proximal tissues.
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